Clinical Efficacy of Ezetimibe Combined with Rosuvastatin in the Treatment of Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Therapy DOI

Zhifeng Wei,

Fang Wang,

Lina Zhang

и другие.

British Journal of Hospital Medicine, Год журнала: 2024, Номер 85(11), С. 1 - 13

Опубликована: Ноя. 30, 2024

Aims/Background Primary hypercholesterolemia (PHC) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although the fact that statins effectively lower low-density lipoprotein cholesterol (LDL-C) levels, some patients fail to achieve target LDL-C levels and continue have high of disease. This study aims evaluate clinical efficacy safety ezetimibe combined with rosuvastatin in PHC. Methods retrospectively examined 101 PHC who received at cardiology department Jilin Province FAW General Hospital, between 2021 2024. Patients were divided into observation (ezetimibe rosuvastatin, n = 45) control (rosuvastatin, 66) groups accordance their treatment regimens. Data sourced from hospital's electronic health records system, statistical analysis was performed by using SPSS 25.0 software (IBM Corporation, Armonk, NY, USA). Results Baseline characteristics similar two groups. After 12 weeks treatment, reduction group (–0.373 [–0.427, –0.348]) greater than (–0.240 [–0.318, –0.222], p < 0.001). The percentage changes total (TC), triglyceride (TG), high-density (HDL-C) significantly better (TC: –0.230 [–0.302, –0.144], TG: –0.292 [–0.333, –0.237], HDL-C: 0.081 [0.067, 0.111]) –0.127 [–0.158, –0.119], –0.082 [–0.101, –0.067], 0.000 [–0.163, 0.133] 0.001, 0.011, respectively). Regarding drug safety, incidence adverse events comparable (11.10% vs. 12.10%, 0.871). Conclusion combination demonstrates superior lipid-lowering good inadequately controlled statin therapy, providing an effective alternative option. Further large-scale, multicenter randomized trials are warranted confirm its long-term safety.

Язык: Английский

Aspirin and clinical outcomes in individuals with incidentally diagnosed coronary artery stenosis DOI
In Tae Jin,

Yangyoun Lee,

Eui‐Young Choi

и другие.

The American Journal of Medicine, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid DOI Creative Commons
Hack‐Lyoung Kim, Jung‐Joon Cha, Sang‐Hak Lee

и другие.

Journal of Lipid and Atherosclerosis, Год журнала: 2025, Номер 14(2), С. 135 - 135

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Are We Using Ezetimibe As Much As We Should? DOI Creative Commons

Antonis A. Manolis,

Theodora A. Manolis,

Dimitri P. Mikhailidis

и другие.

Biomarker Insights, Год журнала: 2024, Номер 19

Опубликована: Янв. 1, 2024

Lipid-lowering therapies, particularly non-statin regimens, are underutilized as ~2/3 of patients with atherosclerotic cardiovascular (CV) disease (CVD) not optimally managed, and do attain target low-density lipoprotein cholesterol (LDL-C) concentrations, despite statin treatment. Statins have been the mainstay hypolipidemic therapies; however, they plagued by adverse effects, which partly hindered their more widespread use. Ezetimibe is often first added mode treatment to LDL-C goals it efficacious also allows use a smaller dose statin, while need for expensive therapies obviated. We herein provide comprehensive review effects ezetimibe in lipid lowering reducing CV events improving outcomes. Of oral ezetimibe, contrast newer agents, most convenient and/or affordable regimen be utilized mono- or combined therapy supported data from outcomes studies attesting its efficacy CVD risk events. When could lower, thus curtailing side-effects, effect enhanced (by ~20%) percentage level (<70 mg/dL) higher versus high-intensity statin. serve an alternative cases intolerance. In conclusion, has excellent safety/tolerability profile; that can targets. therapy, limiting occurrence side-effects.

Язык: Английский

Процитировано

2
2024 KSoLA consensus on secondary dyslipidemia DOI Creative Commons
Hoyoun Won, Jae Hyun Bae, Hyunjung Lim

и другие.

The Korean Journal of Internal Medicine, Год журнала: 2024, Номер 39(5), С. 717 - 730

Опубликована: Авг. 30, 2024

Elevated blood cholesterol and triglyceride levels induced by secondary causes are frequently observed. The identification appropriate handling of these essential for dyslipidemia treatment. Major hypercholesterolemia hypertriglyceridemia include an unhealthy diet, diseases metabolic conditions affecting lipid levels, therapeutic side effects. It is imperative to correct prior initiating conventional lipid-lowering therapy. Guideline-based therapy can then be administered based on the subsequent levels.

Язык: Английский

Процитировано

1
2024 KSoLA Consensus on Secondary Dyslipidemia DOI Creative Commons
Hoyoun Won, Jae Hyun Bae, Hyunjung Lim

и другие.

Journal of Lipid and Atherosclerosis, Год журнала: 2024, Номер 13(3), С. 215 - 215

Опубликована: Янв. 1, 2024

Elevated blood cholesterol and triglyceride levels induced by secondary causes are frequently observed. The identification appropriate handling of these essential for dyslipidemia treatment. Major hypercholesterolemia hypertriglyceridemia include an unhealthy diet, diseases metabolic conditions affecting lipid levels, therapeutic side effects. It is imperative to correct prior initiating conventional lipid-lowering therapy. Guideline-based therapy can then be administered based on the subsequent levels.

Язык: Английский

Процитировано

1
Escalating Lipid Therapy After Achieving LDL-C <70 mg/dL With Moderate-Intensity Statins in High-Risk Patients DOI
Geunhee Park, Eui‐Young Choi, Sang‐Hak Lee

и другие.

Korean Circulation Journal, Год журнала: 2024, Номер 55(5), С. 426 - 426

Опубликована: Дек. 9, 2024

Guidelines recommend target levels of low-density lipoprotein cholesterol (LDL-C) and intensive lipid-lowering therapy (LLT) in high-risk patients. However, the value escalating LLT when LDL-C targets are achieved with moderate-intensity statins is unknown. We aimed to evaluate benefits escalation this population. In retrospective propensity score-matched study, we screened data from two university hospitals between 2006 2021. Of 54,069 patients atherosclerotic cardiovascular disease (ASCVD), 3,205 who <70 mg/dL were included. After 1:3 matching, 1,315 (339 976 without) ultimately examined. The primary outcomes major adverse cerebrovascular events (MACCE)1 (cardiovascular death, nonfatal myocardial infarction, ischemic stroke) all-cause death. During a median follow-up 5.7 years, MACCE1 rate was not significantly lower group than non-escalation (9.8 14.3/1,000 person-years, respectively; hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.43-1.09; p=0.11). Kaplan-Meier curves showed similar results (log-rank risk death did differ groups. MACCE2 rate, which additionally includes coronary/peripheral revascularization, (24.5 35.4/1,000 HR, 0.70; CI, 0.52-0.94; p=0.017). hard ASCVD achieving statins. it had benefit reducing revascularization rates

Язык: Английский

Процитировано

1
Clinical Efficacy of Ezetimibe Combined with Rosuvastatin in the Treatment of Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Therapy DOI

Zhifeng Wei,

Fang Wang,

Lina Zhang

и другие.

British Journal of Hospital Medicine, Год журнала: 2024, Номер 85(11), С. 1 - 13

Опубликована: Ноя. 30, 2024

Aims/Background Primary hypercholesterolemia (PHC) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although the fact that statins effectively lower low-density lipoprotein cholesterol (LDL-C) levels, some patients fail to achieve target LDL-C levels and continue have high of disease. This study aims evaluate clinical efficacy safety ezetimibe combined with rosuvastatin in PHC. Methods retrospectively examined 101 PHC who received at cardiology department Jilin Province FAW General Hospital, between 2021 2024. Patients were divided into observation (ezetimibe rosuvastatin, n = 45) control (rosuvastatin, 66) groups accordance their treatment regimens. Data sourced from hospital's electronic health records system, statistical analysis was performed by using SPSS 25.0 software (IBM Corporation, Armonk, NY, USA). Results Baseline characteristics similar two groups. After 12 weeks treatment, reduction group (–0.373 [–0.427, –0.348]) greater than (–0.240 [–0.318, –0.222], p < 0.001). The percentage changes total (TC), triglyceride (TG), high-density (HDL-C) significantly better (TC: –0.230 [–0.302, –0.144], TG: –0.292 [–0.333, –0.237], HDL-C: 0.081 [0.067, 0.111]) –0.127 [–0.158, –0.119], –0.082 [–0.101, –0.067], 0.000 [–0.163, 0.133] 0.001, 0.011, respectively). Regarding drug safety, incidence adverse events comparable (11.10% vs. 12.10%, 0.871). Conclusion combination demonstrates superior lipid-lowering good inadequately controlled statin therapy, providing an effective alternative option. Further large-scale, multicenter randomized trials are warranted confirm its long-term safety.

Язык: Английский

Процитировано

0